Harbin Medisan Pharmaceutical Co Ltd (SHE:002900) — Market Cap & Net Worth
Market Cap & Net Worth: Harbin Medisan Pharmaceutical Co Ltd (002900)
Harbin Medisan Pharmaceutical Co Ltd (SHE:002900) has a market capitalization of $548.57 Million (CN¥3.75 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #11859 globally and #3406 in its home market, demonstrating a -0.84% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Harbin Medisan Pharmaceutical Co Ltd's stock price CN¥11.85 by its total outstanding shares 316354550 (316.35 Million). Also see balance sheet size of Harbin Medisan Pharmaceutical Co Ltd for a full breakdown of the balance sheet.
Harbin Medisan Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Harbin Medisan Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows change from $765.45 Million to $548.57 Million (-2.59% CAGR). Also see Harbin Medisan Pharmaceutical Co Ltd (002900) cash conversion ratio for how efficiently the company converts equity into cash flow.
Harbin Medisan Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Harbin Medisan Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 002900 share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.40x
Harbin Medisan Pharmaceutical Co Ltd's market cap is 0.40 times its annual revenue
Latest Price to Earnings (P/E) Ratio
7.77x
Harbin Medisan Pharmaceutical Co Ltd's market cap is 7.77 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $765.45 Million | $1.15 Billion | $181.08 Million | 0.67x | 4.23x |
| 2018 | $490.81 Million | $2.17 Billion | $205.81 Million | 0.23x | 2.38x |
| 2019 | $510.07 Million | $2.10 Billion | $177.18 Million | 0.24x | 2.88x |
| 2020 | $404.98 Million | $1.34 Billion | $29.32 Million | 0.30x | 13.81x |
| 2021 | $914.26 Million | $945.80 Million | $350.95 Million | 0.97x | 2.61x |
| 2022 | $614.53 Million | $1.03 Billion | $30.21 Million | 0.60x | 20.34x |
| 2023 | $619.29 Million | $1.19 Billion | $73.66 Million | 0.52x | 8.41x |
| 2024 | $455.98 Million | $1.13 Billion | $58.68 Million | 0.40x | 7.77x |
Competitor Companies of 002900 by Market Capitalization
Companies near Harbin Medisan Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review 002900 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Harbin Medisan Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Harbin Medisan Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Harbin Medisan Pharmaceutical Co Ltd's market cap moved from $765.45 Million to $ 548.57 Million, with a yearly change of -2.59%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥548.57 Million | -4.90% |
| 2025 | CN¥576.81 Million | +26.50% |
| 2024 | CN¥455.98 Million | -26.37% |
| 2023 | CN¥619.29 Million | +0.78% |
| 2022 | CN¥614.53 Million | -32.78% |
| 2021 | CN¥914.26 Million | +125.76% |
| 2020 | CN¥404.98 Million | -20.60% |
| 2019 | CN¥510.07 Million | +3.92% |
| 2018 | CN¥490.81 Million | -35.88% |
| 2017 | CN¥765.45 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Harbin Medisan Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $548.57 Million USD |
| MoneyControl | $548.57 Million USD |
| MarketWatch | $548.57 Million USD |
| marketcap.company | $548.57 Million USD |
| Reuters | $548.57 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Harbin Medisan Pharmaceutical Co Ltd
Harbin Medisan Pharmaceutical Co., Ltd. engages in the research, development, production, and sale chemical pharmaceutical preparations in China. The company offers various drugs for nervous system, cardiovascular system, systemic anti-infective, muscle and skeletal system, nutritional infusion, and body fluid balance infusion; and other products, including oxaliplatin for injection, calcium foli… Read more